Stock Events

Stock Events

Cytophage Technologies 

€0.001000
4
+€0.00+0%Monday 14:18

Statistics

Day High
0.008
Day Low
0.001
52W High
0.008
52W Low
0.001
Volume
18,600
Avg. Volume
-
Mkt Cap
67,685
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-5.35MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics focuses on gene editing technologies, which can be competitive in the biotech field where Cytophage also operates.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine works on genome editing technology, directly competing in the innovative biotechnology sector similar to Cytophage.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another key player in the CRISPR technology space, overlapping with Cytophage's biotech innovations.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals incorporates advanced biotechnological methods for therapeutic solutions, aligning with Cytophage's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, competing in the same broad biotech industry as Cytophage.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, competing in the cutting-edge biotech sector alongside Cytophage.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, similar to Cytophage's market focus.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics specializes in precision genetic medicines using base editing, a new area in the competitive landscape of biotech similar to Cytophage's focus.

About

Cuspis Capital III Ltd. does not have significant operations. It intends to identify, evaluate, and acquire assets or businesses with a view to complete a qualifying transaction. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Show More
CEO
Mr. William W. Ollerhead B.A., M.B.A., MBA
Country
Canada
ISIN
CA2328211081
WKN
000A4ZZ0X

Listings

STU
DE
70G.STU
V
CA
CIII-P.V

0 Comments

Share your thoughts

FAQs

What is Cytophage Technologies stock price today?▼
The current price of 70G.STU is €0.00 EUR — it has increased by +0% in the past 24 hours. Watch Cytophage Technologies stock price performance more closely on the chart.
What is Cytophage Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Cytophage Technologies stocks are traded under the ticker 70G.STU.
What is Cytophage Technologies market cap?▼
Today Cytophage Technologies has the market capitalization of 67,685
What is Cytophage Technologies revenue for the last year?▼
Cytophage Technologies revenue for the last year amounts to 0 EUR.
What is Cytophage Technologies net income for the last year?▼
70G.STU net income for the last year is -5.35M EUR.
In which sector is Cytophage Technologies located?▼
Cytophage Technologies operates in the Finance & Payments sector.
When did Cytophage Technologies complete a stock split?▼
Cytophage Technologies has not had any recent stock splits.
Where is Cytophage Technologies headquartered?▼
Cytophage Technologies is headquartered in Toronto, Canada.